Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective.
Li C, Menon R, Walles M, Singh R, Upreti VV, Brackman D, Lee AJ, Endres CJ, Kumar S, Zhang D, Barletta F, Suri A, Hainzl D, Liao KH, Lalovic B, Beaumont M, Zuo P, Mayer AP, Wei D. Li C, et al. Among authors: endres cj. Clin Pharmacol Ther. 2022 Oct;112(4):754-769. doi: 10.1002/cpt.2448. Epub 2021 Nov 23. Clin Pharmacol Ther. 2022. PMID: 34657311
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl.
Sun H, Cardinal KA, Wienkers L, Chin A, Kumar V, Neace C, Henderson C, Endres CJ, Topletz-Erickson A, Regal K, Vo A, Alley SC, Lee AJ. Sun H, et al. Among authors: endres cj. Cancer Chemother Pharmacol. 2022 Jun;89(6):737-750. doi: 10.1007/s00280-022-04429-z. Epub 2022 Apr 18. Cancer Chemother Pharmacol. 2022. PMID: 35435471
The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment.
Topletz-Erickson AR, Lee AJ, Mayor JG, Sun H, Abdulrasool LI, Rustia EL, Walker LN, Endres CJ. Topletz-Erickson AR, et al. Among authors: endres cj. Clin Pharmacokinet. 2022 Dec;61(12):1761-1770. doi: 10.1007/s40262-022-01183-6. Epub 2022 Dec 5. Clin Pharmacokinet. 2022. PMID: 36471222 Free PMC article. Clinical Trial.
The role of transporters in drug interactions.
Endres CJ, Hsiao P, Chung FS, Unadkat JD. Endres CJ, et al. Eur J Pharm Sci. 2006 Apr;27(5):501-17. doi: 10.1016/j.ejps.2005.11.002. Epub 2005 Dec 20. Eur J Pharm Sci. 2006. PMID: 16364611 Review.
Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.
Suri A, Mould DR, Song G, Collins GP, Endres CJ, Gomez-Navarro J, Venkatakrishnan K. Suri A, et al. Among authors: endres cj. Clin Pharmacol Ther. 2019 Dec;106(6):1268-1279. doi: 10.1002/cpt.1530. Epub 2019 Jul 9. Clin Pharmacol Ther. 2019. PMID: 31152605 Free PMC article. Clinical Trial.
58 results